Abstract
The atypical antipsychotic risperidone combines dopaminergic and serotonergic antagonism. This results in a drug that is both clinically effective, reducing positive and negative symptoms of schizophrenia, and has a low incidence of adverse effects. At a dosage of 4 to 8 mg/day, risperidone is comparable to 10 mg/day of haloperidol. This dosage has a low incidence of extrapyramidal adverse effects and is nonsedative, although it may cause orthostatic hypotension. There is no current evidence for specific biochemical and haematological abnormalities associated with risperidone. Although the clinical benefits appear to outweigh the risks, this drug continues to be a relatively expensive treatment option in the UK. There is therefore a need for a formal cost-utility assessment of risperidone and for comparisons between this drug and other atypical neuroleptics.
Citations
Feb 12, 1998·European Journal of Pharmacology·M IpsenM J Mulvany
Dec 8, 1996·Health Marketing Quarterly·D H TootelianR C Johnson
Sep 21, 2015·Clinical Drug Investigation·Mona DarwishPhilmore Robertson
Apr 1, 1999·Acta Psychiatrica Scandinavica·M BahroJ Strnad
Jan 1, 1997·Journal of Psychopharmacology·F Song
Oct 30, 2003·The Cochrane Database of Systematic Reviews·C RummelS Leucht
May 5, 2000·The Cochrane Database of Systematic Reviews·E KennedyS Gilbody
Jan 21, 2011·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Nov 26, 1998·The British Journal of Psychiatry : the Journal of Mental Science·C KellyS Carey
Nov 28, 1997·The British Journal of Psychiatry : the Journal of Mental Science·Z Dernovsek, R Tavcar
Jan 10, 2017·Frontiers in Psychology·Natassia GoodePaul M Salmon
Feb 11, 1999·The Annals of Pharmacotherapy·J S MarkowitzT R Moore
Jun 14, 2003·The Cochrane Database of Systematic Reviews·R H HunterF Song
Sep 21, 2016·The Cochrane Database of Systematic Reviews·Simon GilbodyArja Tuunainen